SEC Comment Letter 0000000000-25-003489 to ADIAL PHARMACEUTICALS, INC. (ADIL)
ADIAL PHARMACEUTICALS, INC.
Date: April 1, 2025 · CIK: 0001513525 · Accession: 0000000000-25-003489
AI Filing Summary & Sentiment
Reasoning
Letter
Re: Adial Pharmaceuticals, Inc. Draft Registration Statement on Form S-1 Submitted March 27, 2025 CIK No. 0001513525 Dear Vinay Shah:
April 1, 2025
Vinay Shah Chief Financial Officer Adial Pharmaceuticals, Inc. 4870 Sadler Road, Ste 300 Glen Allen, VA 23060
This is to advise you that we do not intend to review your registration statement.
We request that you publicly file your registration statement no later than 48 hours prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Leslie Marlow, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> April 1, 2025 Vinay Shah Chief Financial Officer Adial Pharmaceuticals, Inc. 4870 Sadler Road, Ste 300 Glen Allen, VA 23060 Re: Adial Pharmaceuticals, Inc. Draft Registration Statement on Form S-1 Submitted March 27, 2025 CIK No. 0001513525 Dear Vinay Shah: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement no later than 48 hours prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Leslie Marlow, Esq. </TEXT> </DOCUMENT>